Daily Sepsis Research Analysis
Three impactful studies advance sepsis science across mechanisms, diagnostics, and pediatric risk stratification. A mechanistic paper reveals that hepatocyte-specific GSDMD deficiency worsens sepsis by disrupting non-canonical secretion of anti-inflammatory factors. A large multicenter cohort derives internally validated rules to identify low-risk invasive bacterial infections in 61–90-day-old febrile infants, and an engineering study demonstrates a 2-hour, culture-free pipeline detecting bloods
Summary
Three impactful studies advance sepsis science across mechanisms, diagnostics, and pediatric risk stratification. A mechanistic paper reveals that hepatocyte-specific GSDMD deficiency worsens sepsis by disrupting non-canonical secretion of anti-inflammatory factors. A large multicenter cohort derives internally validated rules to identify low-risk invasive bacterial infections in 61–90-day-old febrile infants, and an engineering study demonstrates a 2-hour, culture-free pipeline detecting bloodstream bacteria at single-digit CFU/mL in spiked human blood.
Research Themes
- Hepatocyte pyroptosis and systemic immunoregulation in sepsis
- Pediatric invasive bacterial infection risk stratification (61–90 days)
- Culture-free rapid detection of bloodstream pathogens
Selected Articles
1. Hepatocyte-Specific GSDMD Deficiency Aggravates Sepsis by Disrupting Non-Canonical Secretion of Anti-Inflammatory Factors.
Using a hepatocyte-specific loss-of-function approach, the study shows that GSDMD in hepatocytes mitigates sepsis severity by enabling non-canonical secretion of anti-inflammatory mediators. Contrary to the pro-inflammatory role of GSDMD in myeloid cells, hepatocyte GSDMD appears immunoregulatory, and its deficiency aggravates systemic inflammation and outcomes in experimental sepsis.
Impact: This work reframes GSDMD biology by uncovering a protective, hepatocyte-specific role in sepsis, identifying a non-canonical secretory pathway as a therapeutic axis. It challenges the paradigm that GSDMD is uniformly deleterious in sepsis.
Clinical Implications: Therapeutic strategies targeting pyroptosis or GSDMD should consider cell type–specific effects; inhibiting hepatocyte GSDMD could be harmful. Augmenting hepatocyte-derived anti-inflammatory secretions may offer novel interventions.
Key Findings
- Hepatocyte-specific GSDMD knockout exacerbates sepsis severity compared with controls.
- Loss of hepatocyte GSDMD disrupts non-canonical secretion of anti-inflammatory mediators.
- GSDMD’s function in sepsis is cell type–dependent, with a protective role in hepatocytes contrasting with pro-inflammatory effects in myeloid cells.
Methodological Strengths
- Cell type–specific genetic manipulation to isolate hepatocyte GSDMD function.
- Mechanistic linkage to secretory pathways rather than correlative expression alone.
Limitations
- Preclinical study; human validation is lacking.
- The breadth of anti-inflammatory mediators and translational biomarkers was not detailed in the abstract.
Future Directions: Validate hepatocyte GSDMD signatures and anti-inflammatory secretome in human sepsis cohorts; assess therapeutic strategies that preserve or enhance hepatocyte non-canonical secretion without amplifying myeloid pyroptosis.
Gasdermin D (GSDMD)-mediated pyroptosis in macrophages plays a clear role in promoting inflammation and mortality in sepsis. The liver is a commonly damaged organ during sepsis and also an important organ for releasing acute response proteins. However, whether pyroptosis occurs and the function of GSDMD in hepatocytes remains unclear. It is surprising to find that hepatocyte-specific GSDMD knockout (GSDMD
2. Prediction Rule to Identify Febrile Infants 61-90 Days at Low Risk for Invasive Bacterial Infections.
In 4952 febrile infants aged 61–90 days across 17 EDs, a simple rule (negative urinalysis and Tmax ≤ 38.9°C) identified low-risk IBI with 86% sensitivity and 59% specificity. In a subset with PCT and ANC, thresholds of PCT ≤ 0.24 ng/mL and ANC ≤ 10,710/mm3 achieved 100% sensitivity and 66% specificity for low-risk classification.
Impact: Provides pragmatic, internally validated thresholds to guide testing and empiric therapy decisions in older young infants—an area with variable practice patterns.
Clinical Implications: When urine and blood tests are obtained, clinicians may use UA/Tmax criteria to identify low-risk infants and consider observation without invasive testing; where available, PCT+ANC can further improve safety. External prospective validation is needed before widespread implementation.
Key Findings
- Among 4952 infants, 2.0% had invasive bacterial infections (1.9% bacteremia without meningitis; 0.1% meningitis).
- Low-risk rule: negative urinalysis and Tmax ≤ 38.9°C (sensitivity 86.0%, specificity 58.9%).
- PCT-based low-risk rule (subset n=1207): PCT ≤ 0.24 ng/mL and ANC ≤ 10,710/mm3 achieved 100.0% sensitivity and 65.8% specificity.
Methodological Strengths
- Large, multicenter dataset with explicit outcome definition and 10-fold cross-validation.
- Clear, actionable thresholds with internal validation and subset biomarker analysis.
Limitations
- Derivation and internal validation only; lacks external prospective validation.
- Biomarker-enhanced rule available in a subset (PCT/ANC), which may limit generalizability.
Future Directions: Prospectively validate both rules across diverse settings; evaluate impact on lumbar puncture rates, antibiotic exposure, missed IBI, and healthcare utilization.
OBJECTIVE: To derive and internally validate a clinical prediction rule to identify febrile infants aged 61-90 days at low risk of invasive bacterial infections (IBIs). METHODS: Using data from 17 Pediatric Emergency Care Applied Research Network Registry (PECARN) emergency departments, we included noncritically ill, previously healthy infants aged 61-90 days with temperatures greater than or equal to 38°C and urinalyses and blood cultures obtained between January 1, 2012, and April 30, 2024. Our outcome was IBI, defined as growth of pathogenic bacteria from blood or cerebrospinal fluid culture. Using recursive partitioning with 10-fold cross-validation, we derived and internally validated a prediction rule using age, temperature, urinalysis (negative/positive), and absolute neutrophil count (ANC) as candidate predictors. Limiting the analysis to infants with procalcitonin (PCT) and ANC results, we evaluated PCT as an additional predictor. RESULTS: Of 4952 infants included, 100 (2.0%) had IBIs, including 95 (1.9%) with bacteremia without meningitis and 5 (0.1%) with bacterial meningitis. The optimal prediction rule identified low-risk infants as those with negative urinalyses and highest temperatures less than or equal to 38.9°C, yielding a sensitivity of 86.0% (95% CI, 77.6-92.1) and specificity of 58.9% (95% CI, 57.5-60.3). In the subset of 1207 infants with PCT and ANC measurements, including 27 (2.2%) with IBIs (2 [0.2%] with bacterial meningitis), we identified PCT of 0.24 ng/mL or less and ANC of 10 710 cells/mm3 or less as low-risk predictors. This PCT-based rule demonstrated sensitivity of 100.0% (95% CI, 87.2-100.0) and specificity of 65.8% (95% CI, 63.0-68.5). CONCLUSIONS: We derived 2 accurate clinical prediction rules to identify febrile infants aged 61-90 days at low risk of IBIs when urine and blood testing are obtained. Prospective validation is needed.
3. Culture-free detection of bacteria from blood for rapid sepsis diagnosis.
An integrated pipeline combining Smart centrifugation, microfluidic trapping, and deep learning detects bloodstream bacteria in spiked human blood within 2 hours at single-digit CFU/mL for key pathogens (E. coli, K. pneumoniae). The method struggled with S. aureus, highlighting organism-specific challenges.
Impact: Demonstrates a feasible culture-free workflow that could compress time-to-identification from days to hours, a critical bottleneck in sepsis care.
Clinical Implications: If validated clinically, this approach could enable early organism-directed therapy, reduce empiric broad-spectrum use, and integrate with rapid susceptibility testing. Current limitations with S. aureus detection must be addressed.
Key Findings
- Two-hour culture-free detection of bacteria from spiked human blood using Smart centrifugation, microfluidics, and deep learning.
- Detection limits: E. coli 9 CFU/mL, K. pneumoniae 7 CFU/mL, E. faecalis 32 CFU/mL.
- Staphylococcus aureus detection remains challenging in this workflow.
Methodological Strengths
- Integrated engineering pipeline with quantified limits of detection on human blood matrices.
- Automated image-based classification leveraging deep learning.
Limitations
- Evaluated on spiked healthy donor blood; no clinical sepsis cohort validation.
- Organism-specific performance gaps (e.g., S. aureus) require optimization.
Future Directions: Prospective clinical validation across diverse pathogens and bacteremia levels; enhance S. aureus capture/classification; integrate rapid susceptibility phenotyping.
Approximately 50 million people suffer from sepsis yearly, and 13 million die from it. For every hour a patient with septic shock is untreated, their survival rate decreases by 8%. Therefore, rapid detection and antibiotic susceptibility profiling of bacterial agents in the blood of sepsis patients are crucial for determining appropriate treatment. Here, we introduce a method to isolate bacteria from whole blood with high separation efficiency through Smart centrifugation, followed by microfluidic trapping and subsequent detection using deep learning applied to microscopy images. We detected, within 2 h, E. coli, K. pneumoniae, or E. faecalis from spiked samples of healthy human donor blood at clinically relevant concentrations as low as 9, 7 and 32 colony-forming units per ml of blood, respectively. However, the detection of S. aureus remains a challenge. This rapid isolation and detection represents a significant advancement towards culture-free detection of bloodstream infections.